Ovid Therapeutics

Filed a patent for "rnai targeting hnrnph2 missense mutations for treatment of bain syndrome" on Tue, June 6, 2023

Filed a patent for "rnai targeting ppp2r5d missense mutations for treatment of jordan’s syndrome" on Tue, June 6, 2023

Filed a patent for "rnai targeting kif1a missense mutations for treatment of kif1a associated neurological disorder" on Tue, June 6, 2023

Filed a patent for "rnai targeting hnrnph2 missense mutations for treatment of bain syndrome" on Wed, November 29, 2023

Filed a patent for "rnai targeting ppp2r5d missense mutations for treatment of jordan’s syndrome" on Wed, November 29, 2023

Filed a patent for "rnai targeting kif1a missense mutations for treatment of kif1a associated neurological disorder" on Wed, November 29, 2023

Filed a patent for "use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of diabetes and pre-diabetes" on Fri, February 17, 2023

Filed a patent for "use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid for gastrointestinal tract disorders and as an immunomodulatory agent" on Fri, February 17, 2023

Filed a patent for "use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of rheumatoid arthritis" on Fri, February 17, 2023

Filed a patent for "use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of multiple sclerosis" on Fri, February 17, 2023

Filed a patent for "use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of diabetes and pre-diabetes" on Thu, August 29, 2024

Filed a patent for "use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid for gastrointestinal tract disorders and as an immunomodulatory agent" on Thu, August 29, 2024

Filed a patent for "use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of rheumatoid arthritis" on Thu, August 29, 2024

Filed a patent for "use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of multiple sclerosis" on Thu, August 29, 2024

Filed a patent for "pharmaceutical formulations containing gaboxadol for therapeutic treatment" on Thu, August 1, 2024

Filed a patent for "methods of treating developmental disorders with gaboxadol" on Thu, March 9, 2023

Filed a patent for "shrna targeting ube3a-ats to restore paternal ube3a gene expression in angelman syndrome" on Thu, October 19, 2023

Filed a patent for "shrna targeting snord115 locations to restore paternal ube3a gene expression in angelman syndrome" on Thu, October 19, 2023

Filed a patent for "methods and compositions for treatment of epileptic disorders" on Thu, September 21, 2023

Filed a patent for "use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders" on Thu, August 17, 2023

Filed a patent for "use of gaboxadol for the treatment of non-24 hour sleep-wake disorder" on Thu, September 14, 2023

Filed a patent for "methods and compositions for treatment of epileptic disorders" on Thu, September 21, 2023

Filed a patent for "use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of cancer" on Thu, January 11, 2024

Filed a patent for "use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere’s disease, tourette’s syndrome, attention deficit hyperactivity disorder and addiction" on Thu, December 21, 2023

Filed a patent for "methods of treating seizure disorders and prader-willi syndrome" on Thu, May 30, 2024